BridgeBio Pharma is rated a Buy due to the commercial launch of Attruby and its promising late-stage pipeline focused on rare genetic diseases. The company's valuation exceeds $14 billion, supported by four potential blockbuster drugs expected by 2030, with key regulatory approvals anticipated in 2026–2027. Challenges include upcoming generic competition and patent expirations for existing drugs, but management highlights Attruby's superior efficacy. A $500 million share buyback and strong clinical progress bolster optimism, though narrowing losses and successful FDA approvals are crucial for further gains.
BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrated early and sustained kidney-protective effects in clinical trials. The drug caused a reversible dip in kidney filtration rate and reduc...
BridgeBio Pharma secured $1 billion through preferred equity investment led by Sixth Street and HealthCare Royalty to support upcoming drug launches and strengthen its financial position. The funding comes as BridgeBio prepares to launch three potent...
BridgeBio Pharma announced that the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia demonstrated significant improvements in height velocity, body proportionality, and arm span compared to placebo. These results, published...
